Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Annals of Neurology
L D JacobsR H Whitham

Abstract

The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability associated with this disease. The purpose of this study was to determine whether interferon beta-1a could slow the progressive, irreversible, neurological disability of relapsing multiple sclerosis. Three hundred one patients with relapsing multiple sclerosis were randomized into a double-blinded, placebo-controlled, multicenter phase III trial of interferon beta-1a. Interferon beta-1a, 6.0 million units (30 micrograms¿, was administered by intramuscular injection weekly. The primary outcome variable was time to sustained disability progression of at least 1.0 point on the Kurtzke Expanded Disability Status Scale (EDSS). Interferon beta-1a treatment produced a significant delay in time to sustained EDSS progression (p = 0.02). The Kaplan-Meier estimate of the proportion of patients progressing by the end of 104 weeks was 34.9% in the placebo group and 21.9% in the interferon beta-1a-treated group. Patients treated with interferon beta-1a also had significantly fewer exacerbations (p = 0....Continue Reading

References

Jul 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·E N StenagerU Bille-Brahe
Feb 1, 1990·Annals of Neurology·A NoronhaM A Jensen
Jul 1, 1989·Journal of Computer Assisted Tomography·K O Lim, A Pfefferbaum
Nov 1, 1988·Neurology·E W Willoughby, D W Paty
Aug 13, 1987·The New England Journal of Medicine·M B BornsteinV Spada
Oct 1, 1982·Archives of Neurology·L JacobsR Ekes
Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Oct 15, 1994·Lancet·D E Goodkin
Apr 1, 1995·Multiple Sclerosis : Clinical and Laboratory Research·J N WhitakerS C Reingold

❮ Previous
Next ❯

Citations

Apr 15, 2000·Journal of Clinical Apheresis·R Weinstein
Mar 24, 1999·Arthritis and Rheumatism·M C LevesqueJ B Weinberg
Mar 29, 2002·Annals of Neurology·Roy W BeckAlfred W Sandrock
Sep 1, 1996·Annals of Neurology·R RudickE Willoughby
Dec 1, 1996·Annals of Neurology·H P Hartung, B C Kieseier
Dec 1, 1996·Annals of Neurology·D W Paty, D K Li
Aug 1, 1997·Annals of Neurology·J A FreemanA J Thompson
Mar 1, 1997·Rehabilitation Nursing : the Official Journal of the Association of Rehabilitation Nurses·K Costello, K Conway
Dec 1, 1996·Italian Journal of Neurological Sciences·D H Miller
Apr 21, 2007·Current Treatment Options in Neurology·Adrienne Boissy, Robert J Fox
Nov 27, 2004·Der Nervenarzt·S Jarius, R Hohlfeld
Apr 7, 2005·Der Nervenarzt·B SchreinerH Wiendl
Nov 26, 2010·Der Nervenarzt·C WarnkeH-P Hartung
Sep 18, 2012·European Journal of Clinical Pharmacology·Silvio GarattiniRita Banzi
Dec 14, 2004·Journal of Neurology·Helen Tremlett, Joel Oger
Nov 19, 2004·Journal of Neurology·Hans-Peter HartungYannis Zoukos
Jan 18, 2005·Journal of Neurology·M Sandberg-WollheimUNKNOWN EVIDENCE Study Group
Jun 10, 2005·Journal of Neurology·Eleonora CoccoMaria Giovanna Marrosu
Sep 10, 2005·Journal of Neurology·Valentina TomassiniCarlo Pozzilli
Sep 20, 2005·Journal of Neurology·Fred Lublin
Sep 20, 2005·Journal of Neurology·Luca Durelli, Marinella Clerico
Sep 20, 2005·Journal of Neurology·Hans-Peter Hartung
Apr 26, 2007·Journal of Neurology·Hans-P HartungPer Soelberg Sorensen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.